THERAPY DOSSIER · th-11f004c8ee0d

Human induced pluripotent stem cell derived endothelial cells overexpressing IL-8 receptors A and B (HiPS-IL8RA/B-ECs), generated using adenoviral vectors

Biologic

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Other
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: HiPS-IL8RA/B-ECs
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 26801304 ↗2016Reported benefit

Targeted delivery of human iPS-ECs overexpressing IL-8 receptors inhibits neointimal and inflammatory responses to vascular injury in the rat.

RatOtherSprague-DawleyMaleIntravenous transfusion1.5 x 10^6 cells per animalImmediately after endoluminal injury

Model: Balloon endoluminal injury of the right carotid artery

HiPS-IL8RA/B-ECs homed to the injured artery, reduced inflammatory mediator expression and inflammatory cell infiltration, accelerated re-endothelialisation and attenuated neointima formation, whereas control HiPS-ECs and HiPS-Null-ECs did not.

Extraction: extract · Supplied extraction confidence: 0.7. Machine-extracted fields require source verification.

Loading the evidence…